Parallax Volatility Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Parallax Volatility Advisers’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-400	Closed	-$18.1K	–	3311
2022 Q4	$18.1K	Sell	400 -5,400	-93%	-$349K	﹤0.01%	2497
2022 Q3	$405K	Buy	+5,800	New	+$429K	﹤0.01%	2058
2022 Q1	–	Sell	-22,900	Closed	-$3.36M	–	3334
2021 Q4	$3.36M	Hold	22,900	–	–	﹤0.01%	911
2021 Q3	$4.05M	Buy	+22,900	New	+$3.68M	﹤0.01%	894
2020 Q2	–	Sell	-4,100	Closed	-$315K	–	2943
2020 Q1	$315K	Sell	4,100 -300	-7%	-$26.9K	﹤0.01%	1872
2019 Q4	$568K	Buy	+4,400	New	+$424K	﹤0.01%	1697
2018 Q3	–	Sell	-47,500	Closed	-$2.34M	–	3806
2018 Q2	$2.34M	Buy	+47,500	New	+$1.79M	﹤0.01%	847

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parallax Volatility Advisers's MRTX Position: Q3 2023 in Review

Parallax Volatility Advisers sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2023, closing a stake of 51,988 shares — an estimated $1.86M sold.

Parallax Volatility Advisers first reported a position in MRTX in Q2 2017 and held it in 13 quarters. The position peaked at $12M in Q2 2019. 213 funds tracked by Wall St. Rank hold MRTX as of Q3 2023.

Parallax Volatility Advisers reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Parallax Volatility Advisers sold 51,988 Mirati Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.86M.
Parallax Volatility Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2017 and held it in 13 quarters.
Parallax Volatility Advisers's Mirati Therapeutics, Inc. Common Stock position peaked at $12M in Q2 2019.
213 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Parallax Volatility Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.